Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Relacorilant in Endogenous Cushing Syndrome
2018-001616-30Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relacorilant in Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoint: Incidence of TEAEs. Started May 2018; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2018-001616-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001616-30.